Abstract
Rhizopus oryzae causes fatal invasive mucormycosis, especially in immunocompromised patients. Posaconazole is used to treat mucormycosis caused by R. oryzae, which is resistant to fluconazole and voriconazole. We evaluated the efficacy of posaconazole against R. oryzae in vivo using a silkworm infection model at 37℃, the human body temperature. The level of pathogenicity differed among the R. oryzae isolates, and posaconazole prolonged the survival of infected silkworms. Therefore, the silkworm infection model is suitable for investigating the virulence factors of R. oryzae and developing antifungal agents for mucormycosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
